Neurology Central

Experimental autism drug balovaptan granted Breakthrough Therapy Designation

0
The FDA has granted Breakthrough Therapy Designation for Roche’s (Basel, Switzerland) investigational autism drug, balovaptan.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Leave A Comment